This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Halozyme Therapeutics’s 8K filing here.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Featured Stories
- Five stocks we like better than Halozyme Therapeutics
- Canada Bond Market Holiday: How to Invest and Trade
- Battle of the Retailers: Who Comes Out on Top?
- Insider Buying Explained: What Investors Need to Know
- HCA Healthcare: Temporary Setbacks, Long-Term Strength
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- MarketBeat Week in Review – 10/28 – 11/1
